로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Integrin alpha V beta 3

Integrin alpha V beta 3

요약

Name:Integrin alpha-V/beta-3
Target Synonym:Integrin alphaVbeta3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Phase 3 Clinical

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

IT3-H52E3-ELISA
Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag FreeHuman ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) ELISA bioactivity

Immobilized Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) with a linear range of 0.01-0.3 μg/mL (QC tested).

IT3-H52E3-MALS-HPLC
Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. ) MALS images

The purity of Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) is more than 85% and the molecular weight of this protein is around 207-253 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag FreeHuman ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) ELISA bioactivity

Immobilized Human Fibronectin at 2 μg/mL (100 μL/well) can bind Human ITGAV&ITGB3 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT3-H52E3) with a linear range of 0.01-0.3 μg/mL (QC tested).

Synonym Name

Integrin alpha V beta 3,ITGAV&ITGB3

Background

Integrin alpha-V/beta-3 (ITGAV:ITGB3) is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrins alpha-IIb/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Also, Integrin alpha-V/beta-3 acts as a receptor for herpes virus 8/HHV-8, coxsackievirus A9, Hantaan virus, cytomegalovirus/HHV-5, human metapneumovirus, human parechovirus 1 and west nile virus. Furthermore, in case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Clinical and Translational Updates

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
68Ga-NOTA-BBN-RGD 68Ga-NOTA-BBN-RGD Phase 1 Clinical Peking Union Medical College Hospital Breast Neoplasms; Prostatic Neoplasms Details
68Ga-NOTA-3PTATE-RGD 68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGD Phase 1 Clinical Peking Union Medical College Hospital Lung Neoplasms Details
(68)Ga-RGD Phase 1 Clinical Peking Union Medical College Hospital Keloid Details
BGC-0222 BGC0222; BGC-0222 Phase 1 Clinical Gaorui Yaoye (Beijing) Technologies Co Ltd, Brightgene Bio-Medical Technology Co Ltd Solid tumours Details
Antiangiotide HM-3; IIM-3 Phase 1 Clinical Inner Mongolia Tianqi Pharmaceutical Group Co Ltd, China Pharmaceutical University Liver Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung Details
[68Ga]-FF58 Details
ProAgio Phase 1 Clinical National Cancer Institute Pancreatic Neoplasms Details
Cilengitide EMD-85189; EMD-121974; NSC-707544 Merck Serono Details
Flotegatide-F18 RGD-F18 Siemens Medical Solution, Assistance Publique Hopitaux De Paris Details
BA 015 gene therapy BA-015 Onxeo Details
SF-0166 SF-0166 Scifluor Life Sciences Details
MK-0429 MK-429; MK-0429; L-000845704 Merck Sharp & Dohme Corp Details
99mTc-3PRGD2 99mTc-3PRGD2 Phase 3 Clinical Peking University Lymphatic Metastasis; Lung Neoplasms Details
Alfatide[18F] 18F-AlF-NOTA-PRGD2; 18F-alfatide; alfatide II; AlF-NOTA-PRGD2-[18F] Phase 3 Clinical Jiangsu Smk Pharmaceutical Co Ltd, Taizhou Kairui Pharmaceutical Technology Co Ltd Carcinoma, Bronchogenic; Head and Neck Neoplasms; Neoplasms; Soft Tissue Neoplasms; Contrast agents; Breast Neoplasms; Lymphoma Details
Pagantangentide Phase 1 Clinical Nanjing Anji Biological Technology Co Ltd, Jiangsu Aotexin Biomedical Technology Co Ltd, China Pharmaceutical University Arthritis, Rheumatoid; Rheumatic Diseases Details
Ga-68 NODAGA-RGD [68Ga]Theranost; Theranost 68Ga-RGD Phase 1 Clinical Advanced Imaging Projects, Zentralklinik Bad Berka, National Cancer Institute Neovascularization, Pathologic Details
IDL-2965 IDL-2965 Phase 2 Clinical Indalo Therapeutics Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis Details

This web search service is supported by Google Inc.

totop